MLAB Earnings Date: Nov 5, 2026 (Estimated) — Mesa Laboratories, Inc.
NASDAQ · Technology · Scientific & Technical Instruments
Updated
When is MLAB's next earnings date?
Mesa Laboratories, Inc. (MLAB) is expected to report Q2 2027 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.29 on revenue of $62.2M.
How did MLAB do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q1 2027), Mesa Laboratories, Inc. posted EPS of $2.68 versus the $2.63 estimate, a beat of 11.7%. Revenue was $60.1M against a $60.9M estimate. The stock's 1-day post-earnings move was +9.5%.
How much does MLAB stock move after earnings?
MLAB beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 10.9% (up or down) in the day after earnings.
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q1 2027 | 2.63 | 2.68 | +11.67% | $60.1M | ✅ Beat | +9.46% | +5.93% | +22.09% |
| 2026-05-27 | Q4 2026 | 1.47 | 3.30 | +124.49% | $63.7M | ✅ Beat | -14.47% | +0.62% | -7.41% |
| 2026-02-03 | Q3 2026 | 1.60 | 3.07 | +91.87% | $65.1M | ✅ Beat | +8.73% | +12.82% | +15.51% |
| 2025-11-06 | Q2 2026 | 1.72 | 2.75 | +59.88% | $60.7M | ✅ Beat | +1.52% | +1.32% | +4.34% |
| 2025-08-05 | Q1 2026 | 2.03 | 2.32 | +14.29% | $59.5M | ✅ Beat | -24.92% | -20.93% | -19.57% |
| 2025-02-04 | Q3 2025 | 1.51 | 2.72 | +80.13% | $62.8M | ✅ Beat | +2.49% | +15.55% | +2.83% |
| 2024-11-07 | Q2 2025 | 1.38 | 2.62 | +89.86% | $57.8M | ✅ Beat | -12.13% | -19.67% | -7.44% |
| 2024-06-05 | Q4 2024 | 2.33 | 2.77 | +18.88% | $58.9M | ✅ Beat | +13.16% | +0.89% | -3.44% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY27 · $60.1M total
| Segment | Share | Revenue | YoY | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| Sterilization and Disinfection Control | 40.7% | $24.5M | -3.6% | — | — | $25.4M | $22.1M |
| Calibration Solutions | 22.1% | $13.3M | +7.6% | — | — | $12.3M | $13.6M |
| Biopharmaceutical Development | 20.1% | $12.1M | +5.0% | — | — | $11.5M | $13.9M |
| Clinical Genomics | 17.1% | $10.3M | -0.1% | — | — | $10.3M | $11.1M |
By region
Q1 FY27 · $60.1M total
| Segment | Share | Revenue | YoY | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 49.5% | $29.7M | +7.6% | $30.5M | $31.2M | $27.6M | $29.3M |
| Other | 41.5% | $25.0M | -5.7% | $26.0M | $25.9M | $26.5M | $26.1M |
| CHINA | 9.0% | $5.4M | +0.1% | $6.3M | $5.0M | $5.4M | $5.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.